Plural Rings Patents (Class 514/679)
  • Patent number: 10550085
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: February 4, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Patent number: 10463738
    Abstract: The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: November 5, 2019
    Assignee: Avanti Polar Lipids, Inc.
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li
  • Patent number: 10085951
    Abstract: The invention provides novel curcuminoid formulations which have improved aqueous solubility and bioavailability when compared to known curcuminoid dosage forms. Formulations of the invention exhibit an enhanced intestinal absorption of curcuminoids, a slower curcuminoid metabolism and a reduced rate of systemic curcuminoid elimination. Additionally, upon administration in vivo, the formulations described and claimed herein produce a high, sustained level of the curcuminoid metabolite tetrahydrocurcumin. For example, at about eight to about ten hours after oral administration to a human, tetrahydrocurcumin plasma levels of between about 50 ng/mL to about 175 ng/mL are detectable, even when that metabolite is absent from the administered formulation. Novel processes for making curcuminoid formulations which have improved aqueous solubility and oral bioavailability, and methods of treating a wide variety of inflammatory, immune and neurogenerative disorders and cancers, are also provided.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: October 2, 2018
    Assignee: DESIGNS FOR HEALTH, INC.
    Inventors: Sarah M. Gannon, Jose A. Llobrera
  • Patent number: 9737502
    Abstract: The present invention discloses the potential of Calebin A in attenuating high fat diet (HFD) induced hepatic steatosis in mammals.
    Type: Grant
    Filed: April 19, 2015
    Date of Patent: August 22, 2017
    Assignee: SAMI LABS LIMITED
    Inventors: Kalyanam Nagabhushanam, Anju Majeed, Muhammed Majeed
  • Patent number: 9676744
    Abstract: Long-chain carboxychromanol compounds useful for treating conditions associated with the need to inhibit cyclooxygenase-1, cyclooxygenase-2, and/or 5-lipoxygenase, and pharmaceutical formulations containing the compounds are provided herein.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 13, 2017
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventor: Qing Jiang
  • Publication number: 20150148292
    Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto.
    Type: Application
    Filed: July 8, 2013
    Publication date: May 28, 2015
    Inventors: Scott D Boden, Sreedhara Sangadala
  • Publication number: 20150147385
    Abstract: Compositions and methods for the treatment of proliferative disorders including proliferative such as breast, uterine cervical, ophthalmic, and pancreatic cancer by the administration of intravenous synthetic curcumin (S-curcumin) are disclosed herein.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventor: Lawrence Helson
  • Publication number: 20150147380
    Abstract: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Inventors: RAPHAEL MANNINO, RUYING LU
  • Publication number: 20150140074
    Abstract: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 21, 2015
    Inventors: RAPHAEL MANNINO, RUYING LU
  • Publication number: 20150132385
    Abstract: The present invention relates to nanocrystalline solid dispersion compositions having discrete particles, wherein each discrete particle comprises crystals of at least one pharmaceutical active; veterinary active; nutraceutical active dispersed in the matrix of at least one crystallization inducer and/or coexisting with crystals of crystallization inducer, optionally along with pharmaceutically acceptable excipients. The present invention also encompasses a novel one-step process for generation of nanocrystalline solid dispersions. The present invention is particularly of use for improving the dissolution of pharmaceutical actives, veterinary actives; nutraceutical actives exhibiting dissolution-limited bioavailability. Dissolution enhancement is because of the decreased crystallite size of the pharmaceutical active.
    Type: Application
    Filed: March 7, 2013
    Publication date: May 14, 2015
    Inventors: Arvind Kumar Bansal, Ajay Kumar Raju Dantuluri, Shete Ganesh Bhaskarao, Pawar Yogesh Bapurao
  • Publication number: 20150125435
    Abstract: Aspects of the invention include compositions for controlling plant parasitic nematodes. Compositions according to certain embodiments include a carbon skeleton energy compound, a chelating agent, macronutrients, micronutrients, an ionophore, exotic micronutrients and a plant parasitic nematode antagonist. Methods for using the compositions of the invention to control plant parasitic nematodes and kits having one or more compositions for controlling plant parasitic nematodes are also described.
    Type: Application
    Filed: August 29, 2014
    Publication date: May 7, 2015
    Inventor: Thomas T. Yamashita
  • Publication number: 20150110877
    Abstract: The invention relates to the treatment of cancer. In one embodiment, the present invention provides a composition comprising a micelle construct attached to a glut-1 antibody and a curcumin molecule. In another embodiment, the present invention provides a method of treating colon and/or breast cancer by administering a therapeutically effective amount of composition comprising a targeted construct attached to an inhibitor of NF-kB.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 23, 2015
    Applicant: IMMIX CORPORATION
    Inventors: Sean Senn, Ilya Rachman
  • Patent number: 9012490
    Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: April 21, 2015
    Assignee: Howard University
    Inventors: Evaristus A. Nwulia, Amol Kulkarni
  • Publication number: 20150087705
    Abstract: Disclosed herein are compounds, compositions and methods for preventing and treating diseases such as intracerebral hemorrhage, cancer, or conditions associated with damaged cells, activated lymphocytes, or microbial products. The disclosed compounds are curcumin analogs. The curcumin analogs possess anti-inflammatory and antioxidant properties, which in part, reduce AP-1 and NF-?B activity.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 26, 2015
    Inventors: Cargill H. Alleyne, JR., Krishnan M. Dhandapani, Ken Wen, MingLiang Ma, WenJing Hu
  • Publication number: 20150080353
    Abstract: The subject invention relates to compositions and methods useful for the in vivo delivery of substantially water-insoluble drugs, like taxol. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 19, 2015
    Inventors: Mewa SINGH, Maninder SANDHU
  • Publication number: 20150072012
    Abstract: A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Ravichandran SRIPATHY, Venkata Narasimha Siva Rama Raju MANDAPATI, Gopaal AJAY, Nirvanashetty SOMASHEKARA, Ramchand Nanappan CHANIYILPARAMPU, Rama Raju GOKARAJU, Ganga Raju GOKARAJU, Kiran BHUPATHIRAJU, Dwarakanath ANJANA
  • Publication number: 20150065431
    Abstract: The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Nax/SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1?, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Inventors: Wei Xu, Seok Jong Hong, Robert D. Galiano, Thomas A. Mustoe
  • Publication number: 20150057362
    Abstract: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.
    Type: Application
    Filed: November 4, 2014
    Publication date: February 26, 2015
    Inventors: William R. Levis, Leonard L. Kaplan, John G. Callahan
  • Publication number: 20150037398
    Abstract: A molecule mixture comprising an amphipathic molecule of type A, which has an overall positive charge in the hydrophilic region, an amphipathic molecule of type B and a polyphenol C, the method for producing the molecule mixture, and the use thereof. The molecules of types A and B are present at a molecular ratio of A:B of 1(±0.2):1(±0.2) mol/mol. A method for producing the mixture and the use is also disclosed.
    Type: Application
    Filed: October 1, 2012
    Publication date: February 5, 2015
    Applicant: FORSCHUNGSZENTRUM JÜLICH GMBH
    Inventors: Agnes Csiszar, Christian Kleusch, Bernd Hoffmann, Rudolf Merkel
  • Publication number: 20150037388
    Abstract: The invention relates, in one aspect, to a mucoadhesive edible slow dissolving film comprising a salt of alginic acid, an edible cellulose derivative, an edible protein, and edible polymer delaying the dissolution in a physiological fluid of the edible film selected from polyvinylpyrrolidone, a carboxyvinyl polymer and mixtures thereof, in an amount effective to delay the dissolution time of the film in a biological fluid. The edible film is suitable for cicatrizing oral ulcerations or lesions or for forming a layer on oral mucosae or gingiva affected by ulcerations or lesions for protecting against mechanical abrasions, infections or caustic agents.
    Type: Application
    Filed: January 28, 2013
    Publication date: February 5, 2015
    Inventor: Sonia Longo
  • Publication number: 20150024060
    Abstract: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 22, 2015
    Applicant: BIOACTIVES LLC
    Inventors: Doddabele L. Madhavi, Daniel I. Kagan
  • Publication number: 20150011494
    Abstract: Curcumin analogues and methods are provided for treatment of disease.
    Type: Application
    Filed: August 1, 2014
    Publication date: January 8, 2015
    Inventors: David L. Vander Jagt, Lorraine M. Deck, Steve F. Abcouwer, Robert A. Orlando, Robert E. Royer, Waylon M. Weber, Ekaterina V. Bobrovnikova-Marjon, Lucy A. Hunsaker
  • Publication number: 20150011620
    Abstract: The present invention relates to the field of anti-invasive compounds and methods for predicting the anti-invasive activity of said compounds, as well as their use in the prevention and/or treatment of diseases associated with undesired cell invasion; in particular, this invention relates to the field of anti-invasive chalcone-like compounds.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 8, 2015
    Inventors: Marc Bracke, Christian Stevens, Tine De Ryck, Bart Roman, Barbara Vanhoecke
  • Patent number: 8916183
    Abstract: This document discloses molecules having the following formulas (“Formula One” &“Formula Two” and “Formula Three”) The Ar1, Het, Ar2, R1, R2, R3, R4, and R5 are further described herein.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: December 23, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: Lindsey G. Fischer, Gary D. Crouse, Thomas C. Sparks, Erich W. Baum
  • Publication number: 20140371327
    Abstract: Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin for oral supplementation against a variety of diseases and method of doing the same is provided.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 18, 2014
    Inventor: Benny Antony
  • Publication number: 20140370110
    Abstract: The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also encompasses a prolamine protein conjugated to a polymer, such as a polyethylene glycol (PEG) chain, which conjugates can be used to prepare micelle assemblies. The invention further encompasses methods of encapsulating molecules using the conjugates of the invention. The micelle assemblies can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of an encapsulated agent in vivo, protecting an encapsulated agent against degradation, and enhancing the water solubility of a drug or other agent.
    Type: Application
    Filed: April 8, 2014
    Publication date: December 18, 2014
    Applicant: SOUTH DAKOTA STATE UNIVERSITY
    Inventors: Omathanu P. Perumal, Satheesh K. Podaralla, Ranjith Kumar Averineni
  • Publication number: 20140371177
    Abstract: A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Charles C-Y Shih, Toshio Kitamura, Qian Shi, Toshiyuki Kawashima, Hui-Kang Wang
  • Publication number: 20140371326
    Abstract: Disclosed is a composition comprising gingerenone A as an active ingredient. The composition includes a food composition for preventing obesity, a pharmaceutical composition for treating obesity and a medicine for treating animal obesity. Since the composition includes gingerenone A, which inhibits expression of the important transcriptional factors C/EBP? and PPAR?, expressed upon adipocyte differentiation, as well as FAS protein expression, the composition has superior potential for obesity prevention or treatment.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 18, 2014
    Applicant: SNU R&DB FOUNDATION
    Inventors: Ki Won Lee, SuJin Seok
  • Publication number: 20140369938
    Abstract: The present invention discloses biocompatible, stable curcumin or its derivatives coated ultra-small super paramagnetic iron oxide nanoparticles (USPION) for biomedical applications. Disclosed herein is also a simple one-pot process for the synthesis of biocompatible, stable curcumin or its derivatives coated ultra-small superparamagnetic iron oxide nanoparticles in absence of a linker or binder. The curcumin or its derivatives coated ultra-small super paramagnetic iron oxide nanoparticles of the present invention retains the medicinal, radical scavenging and fluorescence properties of curcumin.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 18, 2014
    Applicant: Council of Scientific & Industrial Research
    Inventors: Alias Joy Pattayil, Kunnoth Naduvilidam Jayaprabha
  • Publication number: 20140356455
    Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.
    Type: Application
    Filed: December 6, 2013
    Publication date: December 4, 2014
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Parkinson's Institute
    Inventors: Renee Ann Reijo Pera, J. William Langston, Birgitt Schule, Theodore D. Palmer, Blake Byers, Ha Nam Nguyen, James Anthony Byrne, Branden John Cord
  • Publication number: 20140328917
    Abstract: An organic compound nano-powder comprising a granular organic compound with an average particle diameter of 500 nm or less and a 90%-diameter of less than 1500 nm and a carbohydrate compound comprising at least any one of a sugar and a sugar alcohol and with amount of 0.3 times or more by mass relative to amount of the organic compound, a method for producing the same, and a suspension having the organic compound dispersed in a liquid dispersion medium in which the organic compound is insoluble or poorly soluble.
    Type: Application
    Filed: May 11, 2013
    Publication date: November 6, 2014
    Inventors: Takahiro Tada, Kazuhiro Kagami, Shiro Yokota
  • Publication number: 20140322303
    Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.
    Type: Application
    Filed: May 13, 2014
    Publication date: October 30, 2014
    Applicants: Board of Regents, The University of Texas System, SignPath Pharma Inc.
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
  • Publication number: 20140308212
    Abstract: Compositions comprising a therapeutic agent encapsulated by an edible plant-derived microvesicle are provided. Methods of treating an inflammatory disorder and methods of treating a cancer are further provided and include administering an effective amount of a composition comprising a therapeutic agent encapsulated by an edible plant-derived microvesicle to a subject. Further provided are methods of diagnosing a colon cancer that include the steps of administering an edible plant-derived microvesicle incorporating a detectable label to a subject and then determining an amount of the detectable label in an intestine of the subject.
    Type: Application
    Filed: September 20, 2012
    Publication date: October 16, 2014
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventor: Huang-Ge Zhang
  • Patent number: 8859625
    Abstract: The present invention refers to new derivatives of the penta-1,4-dien-3-ones, as well as their processes of preparation. These compounds present strong antitumoral activity and promising antiparasitic action, behaving as almost atoxic by laboratory assays and also by hystopathologic studies. The present invention refers also to a pharmaceutical composition including the referred compounds, method of treatment for cancer and parasitic diseases.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: October 14, 2014
    Assignee: Universidade Bandeirante de Sao Paulo-Academia, Paulista Anchieta S/C Ltda
    Inventors: José Agustin Quincoces Suárez, Durvanei Augusto Maria, Daniela Goncales Rando, Clizete Aparecida Sbravate Martins, Paulo Celso Pardi, Pamela Oliveira De Souza
  • Publication number: 20140303258
    Abstract: Disclosed are the uses of triterpene glycosides as non-toxic natural solubilizing agents for bioactive compounds and/or metabolites thereof. Triterpene glycosides are also shown to solubilize insoluble natural extracts. Also disclosed are exemplary methods and compositions incorporating the uses of triterpene glycosides as non-toxic natural solubilizing agents.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 9, 2014
    Inventors: Muhammed Majeed, Reza Kamarei, Beena Bhat, Natarajan Sankaran
  • Publication number: 20140303109
    Abstract: Water-soluble fluorinated analogs of natural curcumin, and particularly difluoro Knoevenagel condensates and Schiff bases, along with their corresponding copper (H) complexes have improved bioavailablity over curcumin. The fluorine-substituted analogs of curcumin are useful as chemopreventive and/or therapeutic agents against cancers and/or against the development of drug-resistant cancer. A preferred compound is (IE,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene{4(3,4 difluorobenzaldehyde)}-3,5-dione.
    Type: Application
    Filed: March 25, 2011
    Publication date: October 9, 2014
    Inventors: Fazlul H. Sarkar, Subhash Padhye
  • Patent number: 8841326
    Abstract: Curcumin analogs and methods are provided for treatment of disease.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: September 23, 2014
    Assignee: STC.UNM
    Inventors: David L. Vander Jagt, Lorraine M Deck, Steve F. Abcouwer, Robert A. Orlando, Robert E. Royer, Waylon M. Weber, Ekaterina V. Bobrovnikova-Marjon, Lucy A. Hunsaker
  • Publication number: 20140275283
    Abstract: Disclosed is a method for improving the bioavailability of a variety of compounds such as phenolic acids, polyphenols, hydroxyl-cinnamic acids, curcumin, curcumin analogs, curcuminoids, etc., using milk protein concentrate and/or similar milk protein products.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Inventors: Brent L. Petersen, Melinda M. Moss, Niels J. Palmer
  • Patent number: 8835390
    Abstract: The present invention concerns the use of an aquaprin-9 (AQP-9) modulator for the preparation of a pharmaceutical composition for treating or preventing a pathological condition associated with unbalanced osteoclast differentiation. In accordance with one embodiment, the modulator is an AQP-9 inhibitor. An example of AQP-9 inhibitor is phloretin which has been shown to inhibit osteoclast differentiation, following induction of bone marrow cells with RANKL. The invention also concerns methods for modulating osteoclast differentiation, methods for prevention and treating pathological conditions associated with unbalanced osteoclast differentiation as well as pharmaceutical composition comprising such modulators.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: September 16, 2014
    Assignee: Osteobuild Ltd.
    Inventors: Zvi Bar-Shavit, Refael Aharon
  • Patent number: 8835509
    Abstract: The present invention discloses a pharmaceutical composition in the form of self nano emulsifying drug delivery formulation comprising curcuminoids. The pharmaceutical composition of the present invention shows an enhanced drug loading ability, better stability and an improved bioavailability. The composition of the present invention comprises of a pharmaceutically effective amount of a curcuminoid, an oil phase, a surfactant and a co surfactant.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: September 16, 2014
    Assignees: Arbro Pharmaceuticals Ltd., Jamia Hamdard (Hamdard University)
    Inventors: Kanchan Kohli, Sunny Chopra, Saurabh Arora, Roop K. Khar, Kolappa K. Pillai
  • Publication number: 20140255511
    Abstract: The present invention generally relates to the field of medical nutrition. For example, the present invention provides a composition that can be used to treat, prevent and/or reverse muscle atrophy related to immobilization and its consequences. One embodiment of the present invention concerns a composition comprising a leucine and antioxidants that can be used in accelerating muscle recovery after muscle atrophy.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 11, 2014
    Inventors: Dominique Dardevet, Isabelle Savary-Auzeloux, Didier Remond, Lydie Combaret, Gary Williamson, Magali Faure, Denis Breuille
  • Publication number: 20140255502
    Abstract: A pharmaceutical composition is provided. The pharmaceutical composition includes a nanoparticle, a shell and a drug, wherein the nanoparticle has an outer surface and the drug is mixed with the shell and is formed on the outer surface.
    Type: Application
    Filed: September 25, 2013
    Publication date: September 11, 2014
    Applicant: National Chiao Tung University
    Inventors: San-Yuan Chen, Wei-Ming Li
  • Patent number: 8829058
    Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, O or hydroxyl. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: September 9, 2014
    Assignee: Wellstat Therapeutics Corporation
    Inventors: James Dennen O'Neil, Michael K. Bamat, Reid W. von Borstel, Shalini Sharma, Ramachandran Arudchandran
  • Patent number: 8822732
    Abstract: This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: September 2, 2014
    Assignee: AndroScience Corporation
    Inventors: Charles C-Y Shih, Toshio Kitamura, Qian Shi, Toshiyuki Kawashima, Hui-Kang Wang
  • Publication number: 20140242097
    Abstract: A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 28, 2014
    Applicant: THE ROYAL VETERINARY COLLEGE
    Inventors: Liam Good, Kantaraja Chindera, Valentina Gburcik
  • Publication number: 20140242156
    Abstract: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: SignPath Pharma Inc.
    Inventor: Lawrence Helson
  • Publication number: 20140234402
    Abstract: Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: SignPath Pharma Inc.
    Inventor: Lawrence Helson
  • Publication number: 20140227284
    Abstract: Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.
    Type: Application
    Filed: July 23, 2012
    Publication date: August 14, 2014
    Applicant: PACYLEX PHARMACEUTICALS INC.
    Inventors: Luc G. Berthiaume, Erwan Beauchamp, Conganige Maneka Anne Perinpanayagam, Chuiyee Yap
  • Publication number: 20140178314
    Abstract: Personal care compositions for use in an absorbent article are disclosed comprising an isosorbide diester having the formula: wherein R? and R? are independently selected from a straight or branched C1-30 chain, which may be saturated or unsaturated. The personal care compositions also comprise a solid cosmetic active soluble in the isosorbide diester and a dermatologically acceptable carrier. The personal care composition may be in the form of an emulsion. A personal care composition is also disclosed comprising an isosorbide diester having the formula: wherein R? and R? are independently selected from a straight or branched C1-30 chain which may be saturated or unsaturated and Z1-Z6 are independently selected from hydrogen, hydroxyl, amino, amido, R?, or R?. Methods of making the aforementioned personal care compositions are also disclosed.
    Type: Application
    Filed: December 16, 2013
    Publication date: June 26, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Paul Robert Tanner, Larry Richard Robinson
  • Patent number: 8753674
    Abstract: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
    Type: Grant
    Filed: June 3, 2012
    Date of Patent: June 17, 2014
    Assignee: SignPath Pharma Inc.
    Inventor: Lawrence Helson